AbbVie, Genmab land FDA OK for CD3xCD20 bispecific, catching up with Roche
AbbVie and Genmab have landed an accelerated FDA approval for their CD3xCD20 bispecific, adding an option for patients with relapsed/refractory large B cell lymphoma.
While the companies are coming in second after Roche’s Genentech — whose bispecific mosunetuzumab was approved as Lunsumio in December — they note that their drug, epcoritamab, is the first subcutaneous bispecific antibody approved as a third-line treatment of this cancer type. It will be marketed as Epkinly. The treatment has a monthly list price of $37,500, according to a spokesperson, who noted that the average duration of therapy is about nine months.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.